SERA logo

Sera Prognostics (SERA) Company Overview

Profile

Full Name:

Sera Prognostics, Inc.

Sector:

Healthcare

Country:

United States

IPO:

July 15, 2021

Indexes:

Not included

Description:

Sera Prognostics is a healthcare company focused on improving pregnancy outcomes. They develop advanced tests to assess the risk of complications during pregnancy, helping healthcare providers make informed decisions. Their goal is to enhance maternal and fetal health through innovative diagnostic solutions.

Key Details

Price

$4.52

Annual Revenue

$306.00 K(+14.18% YoY)

Annual EPS

-$1.16(+18.88% YoY)

Annual ROE

-42.86%

Beta

0.70

Events Calendar

Earnings

Next earnings date:

Mar 20, 2025

Recent quarterly earnings:

Nov 6, 2024

Recent annual earnings:

Mar 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Aug 10, 23 Citigroup
Neutral
Nov 10, 22 Citigroup
Neutral
Sep 14, 22 Berenberg
Buy
Aug 29, 22 Oppenheimer
Outperform
Apr 27, 22 Berenberg
Buy
Mar 30, 22 Citigroup
Neutral
Nov 19, 21 Oppenheimer
Outperform
Aug 9, 21 William Blair
Outperform
Aug 9, 21 Cowen & Co.
Outperform
Aug 9, 21 Citigroup
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Sera Prognostics to Host Virtual R&D Day on January 31
Sera Prognostics to Host Virtual R&D Day on January 31
Sera Prognostics to Host Virtual R&D Day on January 31
SERA
prnewswire.comJanuary 27, 2025

Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY , Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m.

Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference
Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference
Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference
SERA
prnewswire.comDecember 2, 2024

SALT LAKE CITY , Dec. 2, 2024 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 2:30 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.

Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SERA
prnewswire.comNovember 15, 2024

SALT LAKE CITY , Nov. 15, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.

Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript
Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript
Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript
SERA
seekingalpha.comNovember 7, 2024

Sera Prognostics Inc (NASDAQ:SERA ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Peter DeNardo - IR Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2024 Results. [Operator Instructions] As a reminder, the call is being recorded for replay purposes.

Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates
SERA
zacks.comNovember 6, 2024

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago.

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024
SERA
prnewswire.comOctober 28, 2024

SALT LAKE CITY , Oct. 28, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics, Inc. (SERA) Q2 2024 Earnings Call Transcript
Sera Prognostics, Inc. (SERA) Q2 2024 Earnings Call Transcript
Sera Prognostics, Inc. (SERA) Q2 2024 Earnings Call Transcript
SERA
seekingalpha.comAugust 9, 2024

Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & CEO Austin Aerts - CFO Conference Call Participants Andrew Brackmann - William Blair Dan Brennan - TD Cowen Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review second quarter fiscal year 2024 results. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
SERA
zacks.comAugust 7, 2024

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.34 per share a year ago.

SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
SERA
prnewswire.comAugust 7, 2024

SALT LAKE CITY , Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls) results in international peer-reviewed journal, Diagnostics , with coverage on front page of publication.

Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
SERA
prnewswire.comJuly 9, 2024

Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics SALT LAKE CITY , July 9, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication in Diagnostics, an international, peer-reviewed, open access journal on medical diagnosis, of the top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware. PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay Previously, Sera reported that both co-primary outcomes—reduction of severe neonatal morbidity or neonatal death; and decreased length of neonatal hospital stay—met their endpoints, and the improvements in outcome with a PreTRM® test-and-treat approach were statistically significant.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Sera Prognostics?
  • Does Sera Prognostics pay dividends?
  • What sector is Sera Prognostics in?
  • What industry is Sera Prognostics in?
  • What country is Sera Prognostics based in?
  • When did Sera Prognostics go public?
  • Is Sera Prognostics in the S&P 500?
  • Is Sera Prognostics in the NASDAQ 100?
  • Is Sera Prognostics in the Dow Jones?
  • When was Sera Prognostics's last earnings report?
  • When does Sera Prognostics report earnings?
  • Should I buy Sera Prognostics stock now?

What is the ticker symbol for Sera Prognostics?

The ticker symbol for Sera Prognostics is NASDAQ:SERA

Does Sera Prognostics pay dividends?

No, Sera Prognostics does not pay dividends

What sector is Sera Prognostics in?

Sera Prognostics is in the Healthcare sector

What industry is Sera Prognostics in?

Sera Prognostics is in the Medical Devices industry

What country is Sera Prognostics based in?

Sera Prognostics is headquartered in United States

When did Sera Prognostics go public?

Sera Prognostics's initial public offering (IPO) was on July 15, 2021

Is Sera Prognostics in the S&P 500?

No, Sera Prognostics is not included in the S&P 500 index

Is Sera Prognostics in the NASDAQ 100?

No, Sera Prognostics is not included in the NASDAQ 100 index

Is Sera Prognostics in the Dow Jones?

No, Sera Prognostics is not included in the Dow Jones index

When was Sera Prognostics's last earnings report?

Sera Prognostics's most recent earnings report was on Nov 6, 2024

When does Sera Prognostics report earnings?

The next expected earnings date for Sera Prognostics is Mar 20, 2025

Should I buy Sera Prognostics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions